NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $5.70 -0.14 (-2.40%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.50▼$5.9550-Day Range$4.35▼$6.4552-Week Range$1.50▼$9.39Volume1.23 million shsAverage Volume1.46 million shsMarket Capitalization$651.32 millionP/E RatioN/ADividend YieldN/APrice Target$11.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Applied Therapeutics alerts: Email Address Applied Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside97.4% Upside$11.25 Price TargetShort InterestBearish8.37% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.37Based on 3 Articles This WeekInsider TradingSelling Shares$2.50 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.48) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector187th out of 910 stocksPharmaceutical Preparations Industry77th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.37% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 4.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 1.9 News and Social Media Coverage News SentimentApplied Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Applied Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,503,175.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.48) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 9.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Applied Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Applied Therapeutics Stock (NASDAQ:APLT)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More APLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLT Stock News HeadlinesAugust 15, 2024 | insidertrades.comApplied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman Sells 119,591 SharesSeptember 5 at 3:30 PM | seekingalpha.comApplied Therapeutics: Pushing Towards FDA ApprovalSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 4 at 11:08 AM | finance.yahoo.comApplied Therapeutics to Participate in Upcoming Investor ConferencesAugust 29, 2024 | americanbankingnews.comApplied Therapeutics (NASDAQ:APLT) PT Raised to $8.00August 28, 2024 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Receives $11.00 Average PT from AnalystsAugust 10, 2024 | markets.businessinsider.comOptimistic Buy Rating for Applied Therapeutics Amid Positive Drug Approval ProspectsAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Applied Therapeutics on Strong Govorestat Data and Favorable AdCom PrecedentSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 6, 2024 | finance.yahoo.comApplied Therapeutics, Inc. (NASDAQ:APLT): When Will It Breakeven?August 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Applied Therapeutics (APLT) and SAGE Therapeutics (SAGE)July 31, 2024 | msn.comWilliam Blair Initiates Coverage of Applied Therapeutics (APLT) with Outperform RecommendationJuly 31, 2024 | finance.yahoo.comRare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock UpsideJuly 1, 2024 | globenewswire.comApplied Therapeutics Added to Russell 3000® IndexMay 28, 2024 | seekingalpha.comApplied Therapeutics: Navigating Challenges In ARI Development For Rare DiseasesMay 10, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...May 9, 2024 | investorplace.comAPLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comApplied Therapeutics GAAP EPS of -$0.67 misses by $0.51See More Headlines Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Stock Price Target$11.25 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside+97.4%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net MarginsN/A Pretax Margin-1,198.47% Return on Equity-350.45% Return on Assets-103.09% Debt Debt-to-Equity RatioN/A Current Ratio2.30 Quick Ratio2.30 Sales & Book Value Annual Sales$-333,000.00 Price / Sales-1,955.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book9.05Miscellaneous Outstanding Shares114,267,000Free Float104,440,000Market Cap$651.32 million OptionableOptionable Beta1.99 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Shoshana Shendelman Ph.D. (Age 45)Chair of the Board of Directors, Founder, President, CEO & Secretary Comp: $946.08kMr. Les D. Funtleyder (Age 53)CFO, Principal Financial Officer & Independent Director Comp: $48.75kDr. Riccardo Perfetti M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $860.76kMr. Constantine Chinoporos (Age 58)COO & Chief Business Officer Ms. Catherine Thorpe (Age 60)Chief Accounting Officer Mr. Corwin Dale Hooks (Age 57)Chief Commercial Officer More ExecutivesKey CompetitorsAvid BioservicesNASDAQ:CDMOG1 TherapeuticsNASDAQ:GTHXRigel PharmaceuticalsNASDAQ:RIGLProthenaNASDAQ:PRTAPuma BiotechnologyNASDAQ:PBYIView All CompetitorsInsiders & InstitutionsLogos Global Management LPSold 750,000 shares on 8/27/2024Ownership: 0.525%Perceptive Advisors LLCSold 500,000 shares on 8/16/2024Ownership: 7.006%Frazier Life Sciences Management L.P.Bought 333,278 shares on 8/16/2024Ownership: 2.001%Algert Global LLCBought 23,476 shares on 8/16/2024Ownership: 0.021%The Manufacturers Life Insurance Company Bought 36,824 shares on 8/15/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $3.35 at the start of the year. Since then, APLT stock has increased by 70.1% and is now trading at $5.70. View the best growth stocks for 2024 here. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $10 million. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Top institutional shareholders of Applied Therapeutics include Perceptive Advisors LLC (7.01%), Frazier Life Sciences Management L.P. (2.00%), Peregrine Capital Management LLC (0.64%) and Logos Global Management LP (0.53%). Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder, Stacy J Kanter and Chids Mahadevan. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA) and Verizon Communications (VZ). This page (NASDAQ:APLT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLT Stock Alerts